Insulin glargine (Lantus ®, sanofi-aventis) claims to have a 24-hour duration of action. Is there any advantage to using it twice daily? If so, what patient population might benefit from twice-daily ...

March 11, 2011 — Insulin degludec (Novo Nordisk), a novel, ultra-long-acting basal formulation, provides comparable glycemic control to insulin glargine without additional adverse events and may ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Tip of an insulin injection. Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for ...

Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the first interchangeable biosimilar insulin product to improve glycemic control for children ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...